GLP-1 receptor agonists and serious adverse events: Evidence, uncertainty and clinical implications
This narrative review appraises evidence regarding seven serious adverse events linked to GLP-1 receptor agonists, including thyroid cancer, acute pancreatitis, gallbladder and biliary disease, and others. The authors consider evidence from mechanistic studies, spontaneous reports, randomized trials, and cohort studies. For events such as thyroid cancer and acute pancreatitis, evidence regarding causality remains uncertain. The authors note that because these events are rare, even substantial relative risk increases generally correspond to small absolute risk increases in broad populations.
What to check after reading
This review assesses safety evidence for GLP-1 receptor agonists, noting that causality evidence remains uncertain for certain serious adverse events and that absolute risk increases are generally small due to rarity.
Source
Calendar dates show when a case was added or scheduled. For event dates, check the original source.